SynapseBone combines pulsed electromagnetic fields, therapeutic ultrasound, and adaptive AI to pioneer precise, non-invasive skeletal adaptation technology.
Bone density loss is a silent epidemic. Conventional approaches treat symptoms. SynapseBone targets the underlying biology — delivering precisely calibrated stimuli that engage the body's natural adaptive mechanisms.
Our platform integrates multi-modal physical stimulation with real-time AI feedback loops, enabling intelligent, patient-specific therapy protocols that evolve with each session.
See How It WorksBuild technology that makes bone density loss preventable — not just manageable — through intelligent, non-invasive stimulation systems backed by rigorous science.
A world where adaptive AI and precision biophysics converge — enabling personalized skeletal health interventions accessible to patients, clinicians, and researchers globally.
Each modality targets a distinct biological pathway. Together, they form a synergistic stimulation protocol governed by adaptive AI.
Precisely tuned PEMF waveforms interact with bone cell membranes to modulate ion transport, promote osteoblast activity, and activate endogenous repair signaling pathways.
Low-intensity pulsed ultrasound (LIPUS) applies mechanical acoustic pressure at the cellular level, stimulating mechano-transduction pathways associated with bone formation and mineral deposition.
An embedded AI engine continuously interprets biometric and session response data to dynamically adjust stimulation parameters — optimizing efficacy across individual patient profiles and treatment stages.
Every design decision traces back to peer-reviewed biophysics and orthopedic research. We are building from established science toward a rigorous clinical evidence base.
Decades of published research demonstrate that electromagnetic fields modulate osteoblast and osteoclast activity. SynapseBone builds on this foundation with programmable, precision-controlled waveform delivery.
Bone is mechanosensitive. LIPUS applies controlled mechanical stress at the cellular level, engaging integrin-mediated signaling cascades that are implicated in bone matrix synthesis and mineralization.
Static stimulation protocols are a limitation of current devices. Our AI layer treats each session as a data point — continuously refining protocol parameters based on physiological response signals.
SynapseBone is positioned at the intersection of orthopedic medicine, AI hardware, and regenerative health — a market undergoing fundamental transformation.
The global bone stimulator market is projected to exceed $1.5B by 2030, driven by aging populations, osteoporosis prevalence, and demand for non-surgical orthopedic interventions.
FDA reclassified non-invasive bone growth stimulators from Class III to Class II in May 2026 — enabling the 510(k) pathway and substantially reducing regulatory risk for market entry.
We are actively seeking partnerships with orthopedic research centers, clinical institutions, and strategic investors aligned with evidence-based medical device innovation.
We welcome conversations with investors, clinical partners, and research institutions.
Start a ConversationWhether you are an investor, a clinical researcher, a regulatory expert, or a potential partner — we want to hear from you.
We are a pre-revenue, founder-led company currently focused on regulatory engagement, clinical partnerships, and IP development. Serious inquiries only.